@manueldomine : Some of the researchers who have been developing lurbinectidin @PhrmMar for the treatment of SCLC for several years, following the presentation of the IMforte study at #ASCO25 @LuisPaz_Ares Santi Ponce,@JonZugazagoitia @Tony_Calles @ManuelDomine @iisgmaranon @Hospital

Manuel Dómine, MD, PhD

@manueldomine

+ Follow

Associate Head Oncology. Fundación Jiménez Díaz. IIS - FJD. Oncohealth Institute @quironsalud Head Thoracic Oncology & Clinical Trials. Professor @UAM_Madrid

ID: 985864516801003520

linkhttp://www.quironsalud.es calendar_today16-04-2018 12:56:32

1,1K Tweet

2,2K Takipçi

1,1K Takip Edilen

Manuel Dómine, MD, PhD

@manueldomine

23 days ago

Some of the researchers who have been developing lurbinectidin PharmaMar for the treatment of SCLC for several years, following the presentation of the IMforte study at #ASCO25 Luis Paz-Ares Santi Ponce,Jon Zugazagoitia Dr. Antonio Calles 🫁🚭 Manuel Dómine, MD, PhD Instituto de Investigación Gregorio Marañón Fundación Jiménez Díaz #LCSM

Some of the researchers who have been developing lurbinectidin <a href="/PhrmMar/">PharmaMar</a> for the treatment of SCLC for several years, following the presentation of the IMforte study at #ASCO25 <a href="/LuisPaz_Ares/">Luis Paz-Ares</a> Santi Ponce,<a href="/JonZugazagoitia/">Jon Zugazagoitia</a> <a href="/Tony_Calles/">Dr. Antonio Calles 🫁🚭</a> <a href="/ManuelDomine/">Manuel Dómine, MD, PhD</a> <a href="/iisgmaranon/">Instituto de Investigación Gregorio Marañón</a> <a href="/Hospital_FJD/">Fundación Jiménez Díaz</a> #LCSM

thumb_up_off_alt40

chat_bubble_outline1

repeat5

shareShare